Blog
-
ETF Product Refresh 2019
The ETF was originally conceived as a way of assisting providers and patients in the prevention of diabetic foot complications through improved diagnosis and tracking of diabetic peripheral neuropathy (DPN). With this is mind, the company is pleased to announce our latest product updates. Customer feedback combined with the latest evidenced-based research has resulted in […]
-
Evidence-based Assessment of Pediatric Diabetic Peripheral Neuropathy
Dr. O’Brien recently published a new article on pediatric diabetic peripheral neuropathy. Evidence-based guidelines for tracking pedal neurological status are reviewed in this sometimes overlooked patient population.
-
Innomed Now Offering OrthoLucent™ O’Brien Bone Clamp
The company is pleased to announce the release of Innomed’s latest version of the O’Brien clamp. It’s made of a carbon fiber PEEK material that is strong, lightweight, completely radiolucent, can be steam sterilized, and helps to prevent from marring component surfaces.
-
New Study Confirms Neuropathy as Leading Risk Factor for Diabetic Ulcers
A large new study has found that 98% of those diabetic patients with foot ulcers had neuropathy signs. Kahn et al assessed 2052 diabetic patients with and without diabetic foot ulcers (DFU). The leading risk factor by far in the DFU group was neuropathy followed by obesity, waist circumference and dyslipidemia. Interestingly, over 17% of […]
-
MIPS Quality Measure #126-Diabetic Foot Neurological Exam
CMS has recently updated its MIPS (Merit-based Incentive Payment System) Quality Measures. Measure #126 continues to be retained for performance of neurological exams on the feet of diabetic patients. As Measure Steward for this indicator, APMA (American Podiatric Medical Association) has done an excellent job creating a flowchart on implementation. Consistent with prior years, […]